1459P - Serum factors of angiogenesis and the growth of fibroblasts in osteogenic sarcoma

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Bone Sarcomas
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Sundr Urunbaev
Citation Annals of Oncology (2014) 25 (suppl_4): iv494-iv510. 10.1093/annonc/mdu354
Authors S. Urunbaev, K.G. Abdikarimov, D.S. Polatova
  • Bone And Soft Tissue Sarcomas, National Cancer Center of Uzbekistan, 100174 - Tashkent/UZ



The purpose of our research was to study the levels of endostatin, FFG 1, VEGF in osteogenic sarcoma patients' peripheric blood serum before conducting treatment in order to detect their possible relationship with clinical characteristic diseases and prognosis.


We have studied 76 patients with osteogenic sarcoma of tubular bones. The received data showed that the levels in blood serum of patients with osteogenic sarcoma FFG-1 and endostatin composed 96±14.5pg/ml and 146.7±3.8 ng/ml, respectively, which compared with 287.8±1.9 pk/ml and 56.5±0.98 ng/ml in healthy people.


The expression of FFG-1 is possible and endostatin may have a connection with pathogenetic changes dealing with the growth of bone tumors. Serum concentrations of VEGF in 71.5% patients with osteogenic sarcoma were increased by 14.3 times (520±68.5 ng/ml in patients) compared with the data from the control group (36.3±0.5 ng/ml). On the basis of laboratory and clinical research the threshold concentration and connection of serum VEGF, FFG-1 and endostatin with clinical course and prognosis of disease were determined. At the level of FFG-1 less than 35.0 pg/ml 3-year survival was 94% but more than 350 pg/ml - 64%. There is also a relationship between the level of malignization of tumor and contents of VEGF in blood serum;, dependence between the concentration of VEGF, metastatic potential of osteogenic sarcoma and the term of metastasis were detected.


Comparative research of VEGF, FFG-1 and endostatin levels in primary tumor of patients with OS can be used as criteria of prognosis of disease and introduced into the scheme of complex therapy preparations, so influencing the expression of VEGF, FFG-1 and endostatin in patients with primary neoplasms of bones with the purpose of increasing the efficacy of therapy.


All authors have declared no conflicts of interest.